Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. TPST
stocks logo

TPST

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-3.520
-12.66%
--
--
-3.640
+15.19%
--
--
-4.030
+94.69%
Estimates Revision
The market is revising No Change the revenue expectations for Tempest Therapeutics, Inc. (TPST) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -68.88%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-68.88%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Tempest Therapeutics Inc (TPST.O) is -0.22, compared to its 5-year average forward P/E of -1.25. For a more detailed relative valuation and DCF analysis to assess Tempest Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.25
Current PE
-0.22
Overvalued PE
-0.32
Undervalued PE
-2.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.69
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.53
Undervalued EV/EBITDA
-1.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TPST News & Events

Events Timeline

(ET)
2025-11-25
08:04:50
Tempest Therapeutics sets price for 1.17 million shares at $3.63 in direct registered offering
select
2025-11-05 (ET)
2025-11-05
08:31:47
Tempest Therapeutics Announces Q3 EPS of (79c) Compared to ($5.32) in the Previous Year
select
2025-08-11 (ET)
2025-08-11
16:54:18
Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-27Newsfilter
Tempest Therapeutics Closes $4.25 Million Registered Direct Offering
  • Successful Financing: Tempest Therapeutics has completed a registered direct offering of 1,172,414 shares at $3.625 per share, raising approximately $4.25 million, which provides essential liquidity to support its clinical development efforts.
  • Short-Term Warrants Issued: The company concurrently issued short-term unregistered warrants allowing the purchase of the same number of shares at an exercise price of $3.50, potentially generating an additional $4.1 million if fully exercised, enhancing future financial flexibility.
  • Market Compliance: This financing adheres to Nasdaq regulations, ensuring the company's compliance in capital markets, which boosts investor confidence and lays the groundwork for future fundraising efforts.
  • Clear Use of Proceeds: The company intends to use the net proceeds primarily for working capital and general corporate purposes, demonstrating its commitment to ongoing operations and R&D investments aimed at advancing its cancer therapeutics to market.
[object Object]
Preview
5.0
11-24NASDAQ.COM
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
  • Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.

  • Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.

  • General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.

  • Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.

[object Object]
Preview
4.5
11-20Benzinga
Crude Oil Declines More Than 2%; Lowe's Stock Rises Following Q3 Earnings Report
  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones down 0.23%, while the NASDAQ and S&P 500 saw slight gains of 0.19% and 0.08%, respectively.

  • Lowe's Earnings Report: Lowe's Companies, Inc. shares rose over 5% after exceeding profit expectations for Q3, reporting adjusted earnings per share of $3.06, although sales fell slightly short.

  • Notable Stock Movements: WeShop Holdings saw a dramatic 413% increase following its Nasdaq debut, while Agios Pharmaceuticals and Carver Bancorp experienced significant declines of 50% and 51%, respectively.

  • Commodity and Economic Updates: Oil prices fell by 2.4% to $59.26, while gold and silver saw slight increases. The U.S. trade deficit narrowed to $59.6 billion in August, with a notable decline in crude oil inventories.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tempest Therapeutics Inc (TPST) stock price today?

The current price of TPST is 3.42 USD — it has increased 4.59 % in the last trading day.

arrow icon

What is Tempest Therapeutics Inc (TPST)'s business?

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.

arrow icon

What is the price predicton of TPST Stock?

Wall Street analysts forecast TPST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TPST is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tempest Therapeutics Inc (TPST)'s revenue for the last quarter?

Tempest Therapeutics Inc revenue for the last quarter amounts to -3.60M USD, decreased -65.91 % YoY.

arrow icon

What is Tempest Therapeutics Inc (TPST)'s earnings per share (EPS) for the last quarter?

Tempest Therapeutics Inc. EPS for the last quarter amounts to -6779000.00 USD, decreased -33.52 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tempest Therapeutics Inc (TPST)'s fundamentals?

The market is revising No Change the revenue expectations for Tempest Therapeutics, Inc. (TPST) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -68.88%.
arrow icon

How many employees does Tempest Therapeutics Inc (TPST). have?

Tempest Therapeutics Inc (TPST) has 24 emplpoyees as of December 05 2025.

arrow icon

What is Tempest Therapeutics Inc (TPST) market cap?

Today TPST has the market capitalization of 16.85M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free